Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 7, 2025

Brilliant Violet 510(TM) anti-human CD4

RRID:AB_2561866 Type: Antibody

Proper Citation

(BioLegend Cat# 317444, RRID:AB_2561866)

Antibody Information

URL: http://antibodyregistry.org/AB_2561866

Proper Citation: (BioLegend Cat# 317444, RRID:AB_2561866)

Target Antigen: CD4

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 510(TM) anti-human CD4

Description: This monoclonal targets CD4

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone OKT4

Antibody ID: AB_2561866

Vendor: BioLegend

Catalog Number: 317444

Alternative Catalog Numbers: 317443

Record Creation Time: 20231110T035227+0000

Record Last Update: 20240725T064717+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 510(TM) anti-human CD4.

No alerts have been found for Brilliant Violet 510(TM) anti-human CD4.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 17 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Prinz LF, et al. (2024) An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL. Cell reports. Medicine, 5(2), 101421.

Ma R, et al. (2024) Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. Cell reports. Medicine, 5(7), 101628.

Gutierrez E, et al. (2023) An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses. Med (New York, N.Y.), 4(5), 326.

Tan X, et al. (2023) ERK Inhibition Promotes Engraftment of Allografts by Reprogramming T-Cell Metabolism. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e2206768.

Vijayakumar B, et al. (2022) Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease. Immunity, 55(3), 542.

Janssen JJE, et al. (2022) Extracellular flux analyses reveal differences in mitochondrial PBMC metabolism between high-fit and low-fit females. American journal of physiology. Endocrinology and metabolism, 322(2), E141.

Menges D, et al. (2022) Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort. Nature communications, 13(1), 4855.

Breen EC, et al. (2022) Accelerated aging with HIV begins at the time of initial HIV infection. iScience, 25(7), 104488.

Caduff N, et al. (2021) KSHV infection drives poorly cytotoxic CD56-negative natural killer

cell differentiation in vivo upon KSHV/EBV dual infection. Cell reports, 35(5), 109056.

Kasper M, et al. (2021) Intraocular dendritic cells characterize HLA-B27-associated acute anterior uveitis. eLife, 10.

Krämer B, et al. (2021) Early IFN-? signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19. Immunity, 54(11), 2650.

Clayton KL, et al. (2021) HIV-infected macrophages resist efficient NK cell-mediated killing while preserving inflammatory cytokine responses. Cell host & microbe, 29(3), 435.

Looman KIM, et al. (2021) Childhood Adiposity Associated With Expanded Effector Memory CD8+ and V?2+V?9+ T Cells. The Journal of clinical endocrinology and metabolism, 106(10), e3923.

De Domenico E, et al. (2020) Optimized workflow for single-cell transcriptomics on infectious diseases including COVID-19. STAR protocols, 1(3), 100233.

Meckiff BJ, et al. (2020) Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19. Cell, 183(5), 1340.

Ott M, et al. (2020) Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration. JCI insight, 5(17).

Schulte-Schrepping J, et al. (2020) Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. Cell, 182(6), 1419.